Monoclonal antibodyPhase 3 trialInvestigational
Dinutuximab beta
How it works
Dinutuximab beta binds to GD2, a protein found on the surface of certain cancer cells, leading to cancer cell death.
Cancer types
Colorectal Cancer— All patients
Efficacy
In clinical trials, dinutuximab beta improved response rates and survival in patients with metastatic colorectal cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.